JP Morgan Private Wealth Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,837	Closed	-$197K	–	2057
2021 Q3	$197K	Buy	+25,837	New	+$219K	﹤0.01%	1866
2019 Q3	–	Sell	-42,690	Closed	-$114K	–	1499
2019 Q2	$114K	Hold	42,690	–	–	﹤0.01%	1332
2019 Q1	$203K	Sell	42,690 -4,660	-10%	-$12.2K	﹤0.01%	1373
2018 Q4	$114K	Hold	47,350	–	–	﹤0.01%	1385
2018 Q3	$208K	Sell	47,350 -25,000	-35%	-$139K	﹤0.01%	1463
2018 Q2	$521K	Buy	72,350 +10,000	+16%	+$68K	﹤0.01%	994
2018 Q1	$321K	Buy	62,350 +49,350	+380%	+$351K	﹤0.01%	1019
2017 Q4	$49K	Buy	+13,000	New	+$33.9K	﹤0.01%	1266
2017 Q1	–	Sell	-10,000	Closed	-$49K	–	1382
2016 Q4	$49K	Hold	10,000	–	–	﹤0.01%	1225
2016 Q3	$77K	Hold	10,000	–	–	﹤0.01%	1195
2016 Q2	$56K	Hold	10,000	–	–	﹤0.01%	1231
2016 Q1	$54K	Buy	+10,000	New	+$58.1K	﹤0.01%	1186

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Private Wealth Advisors's SRNE Position: Q4 2021 in Review

JP Morgan Private Wealth Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 25,837 shares — an estimated $197K sold.

JP Morgan Private Wealth Advisors first reported a position in SRNE in Q1 2016 and held it in 12 quarters. The position peaked at $521K in Q2 2018. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

JP Morgan Private Wealth Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 25,837 Sorrento Therapeutics, Inc. shares in Q4 2021, an estimated $197K.
JP Morgan Private Wealth Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2016 and held it in 12 quarters.
JP Morgan Private Wealth Advisors's Sorrento Therapeutics, Inc. position peaked at $521K in Q2 2018.
234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.